Michel Vounatsos (Biogen via YouTube)

Ex­clu­sive: FDA prob­ing death of Aduhelm pa­tient as Bio­gen's Alzheimer's drug con­tin­ues to stir con­tro­ver­sy

The FDA tells End­points News to­day that it’s aware of the death of a pa­tient tak­ing Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm (ad­u­canum­ab) and is “ac­tive­ly in­ves­ti­gat­ing” the case.

Their state­ment fol­lows the lat­est com­ments from RBC an­a­lyst Bri­an Abra­hams, who is back with an up­date on the death, and this time he says that there are sol­id rea­sons to be­lieve that the event was like­ly drug re­lat­ed and may have been pre­ventable.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.